[1] |
Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T⁃cell lymphoma[J]. JAMA Dermatol, 2013,149(11):1295⁃1299. doi: 10.1001/jamadermatol.2013.5526.
|
[2] |
Ghazawi FM, Netchiporouk E, Rahme E, et al. Comprehensive analysis of cutaneous T⁃cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy[J]. Cancer, 2017,123(18):3550⁃3567. doi: 10.1002/cncr.30758.
|
[3] |
Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sézary syndrome[J]. Lancet, 2008,371(9616):945⁃957. doi: 10. 1016/S0140⁃6736(08)60420⁃1.
|
[4] |
van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome[J]. Blood, 2009,113(1):127⁃136. doi: 10.1182/ blood⁃2008⁃04⁃153031.
|
[5] |
Scarisbrick JJ, Woolford AJ, Russell⁃Jones R, et al. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T⁃cell lymphoma and possible association with homozygous deletion of PTEN[J]. Blood, 2000,95(9):2937⁃2942.
|
[6] |
Scarisbrick JJ, Woolford AJ, Russell⁃Jones R, et al. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p[J]. J Invest Dermatol, 2001,117(3):663⁃670. doi: 10.1046/j.0022⁃202x.2001.01460.x.
|
[7] |
Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T⁃cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides[J]. Br J Dermatol, 2002,147(3):464⁃475. doi: 10.1046/ j.1365⁃2133.2002.04966.x.
|
[8] |
Scarisbrick JJ, Woolford AJ, Calonje E, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome[J]. J Invest Dermatol, 2002,118(3):493⁃499. doi: 10.1046/j.0022⁃202x.2001.01682.x.
|
[9] |
Fischer TC, Gellrich S, Muche JM, et al. Genomic aberrations and survival in cutaneous T cell lymphomas[J]. J Invest Dermatol, 2004,122(3):579⁃586. doi: 10.1111/j.0022⁃202X.2004.22301.x.
|
[10] |
Prochazkova M, Chevret E, Mainhaguiet G, et al. Common chromosomal abnormalities in mycosis fungoides transformation[J]. Genes Chromosomes Cancer, 2007,46(9):828⁃838. doi: 10. 1002/gcc.20469.
|
[11] |
Salgado R, Servitje O, Gallardo F, et al. Oligonucleotide array⁃CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides[J]. J Invest Dermatol, 2010,130(4):1126⁃1135. doi: 10.1038/jid.2009.306.
|
[12] |
Laharanne E, Oumouhou N, Bonnet F, et al. Genome⁃wide analysis of cutaneous T⁃cell lymphomas identifies three clinically relevant classes[J]. J Invest Dermatol, 2010,130(6):1707⁃1718. doi: 10.1038/jid.2010.8.
|
[13] |
Woollard WJ, Kalaivani NP, Jones CL, et al. Independent loss of methylthioadenosine phosphorylase (MTAP) in primary cutaneous T⁃cell lymphoma[J]. J Invest Dermatol, 2016,136(6):1238⁃1246. doi: 10.1016/j.jid.2016.01.028.
|
[14] |
Park J, Yang J, Wenzel AT, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain⁃of⁃function alteration in RLTPR (p.Q575E)[J]. Blood, 2017,130(12):1430⁃1440. doi: 10.1182/blood⁃2017⁃02⁃768234.
|
[15] |
Bastidas Torres AN, Najidh S, Tensen CP, et al. Molecular advances in cutaneous T⁃cell lymphoma[J]. Semin Cutan Med Surg, 2018,37(1):81⁃86. doi: 10.12788/j.sder.2018.007.
|
[16] |
Ungewickell A, Bhaduri A, Rios E, et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2[J]. Nat Genet, 2015,47(9):1056⁃1060. doi: 10.1038/ng.3370.
|
[17] |
McGregor JM, Crook T, Fraser⁃Andrews EA, et al. Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas[J]. J Invest Dermatol, 1999,112(3):317⁃321. doi: 10.1046/j. 1523⁃1747.1999.00507.x.
|
[18] |
McGirt LY, Jia P, Baerenwald DA, et al. Whole⁃genome sequencing reveals oncogenic mutations in mycosis fungoides[J]. Blood, 2015,126(4):508⁃519. doi: 10.1182/blood⁃2014⁃11⁃611194.
|
[19] |
Dereure O, Levi E, Vonderheid EC, et al. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin[J]. J Invest Dermatol, 2002,118(6):949⁃956. doi: 10.1046/j.1523⁃1747.2002.01794.x.
|
[20] |
Nagasawa T, Takakuwa T, Takayama H, et al. Fas gene mutations in mycosis fungoides: analysis of laser capture⁃microdissected specimens from cutaneous lesions[J]. Oncology, 2004,67(2):130⁃134. doi: 10.1159/000080999.
|
[21] |
Vaqué JP, Gómez⁃López G, Monsálvez V, et al. PLCG1 mutations in cutaneous T⁃cell lymphomas[J]. Blood, 2014,123(13):2034⁃2043. doi: 10.1182/blood⁃2013⁃05⁃504308.
|
[22] |
Caumont C, Gros A, Boucher C, et al. PLCG1 gene mutations are uncommon in cutaneous T⁃cell lymphomas[J]. J Invest Dermatol, 2015,135(9):2334⁃2337. doi: 10.1038/jid.2015.161.
|
[23] |
Tensen CP. PLCG1 gene mutations in cutaneous T⁃cell lymphomas revisited[J]. J Invest Dermatol, 2015,135(9):2153⁃2154. doi: 10.1038/jid.2015.221.
|
[24] |
da Silva Almeida AC, Abate F, Khiabanian H, et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome[J]. Nat Genet, 2015,47(12):1465⁃1470. doi: 10.1038/ng.3442.
|
[25] |
Chang LW, Patrone CC, Yang W, et al. An integrated data resource for genomic analysis of cutaneous T⁃cell lymphoma[J]. J Invest Dermatol, 2018,138(12):2681⁃2683. doi: 10.1016/j.jid.2018.06.176.
|
[26] |
Krummel MF, Allison JP. CD28 and CTLA⁃4 have opposing effects on the response of T cells to stimulation[J]. J Exp Med, 1995,182(2):459⁃465. doi: 10.1084/jem.182.2.459.
|
[27] |
Wang L, Ni X, Covington KR, et al. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes[J]. Nat Genet, 2015,47(12):1426⁃1434. doi: 10.1038/ng.3444.
|
[28] |
Sekulic A, Liang WS, Tembe W, et al. Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion[J]. Mol Genet Genomic Med, 2015,3(2):130⁃136. doi: 10.1002/mgg3.121.
|
[29] |
Bastidas Torres AN, Cats D, Mei H, et al. Genomic analysis reveals recurrent deletion of JAK⁃STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides[J]. Genes Chromosomes Cancer, 2018,57(12):653⁃664. doi: 10.1002/gcc. 22679.
|
[30] |
Pulitzer M, Myskowski PL, Horwitz SM, et al. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors[J]. Pathology, 2014,46(7):610⁃616. doi: 10. 1097/PAT.0000000000000166.
|
[31] |
Herrmann JL, Hughey LC. Recognizing large⁃cell transformation of mycosis fungoides[J]. J Am Acad Dermatol, 2012,67(4):665⁃672. doi: 10.1016/j.jaad.2011.12.011.
|
[32] |
Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal[J]. J Clin Oncol, 2010,28(31):4730⁃4739. doi: 10.1200/JCO.2009.27.7665.
|
[33] |
Raghavan SS, Hong EK, Kim YH, et al. Utility of CD30, Ki⁃67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation[J]. J Cutan Pathol, 2019,46(1):33⁃43. doi: 10.1111/cup.13375.
|
[34] |
Pérez C, Mondéjar R, García⁃Díaz N, et al. Advanced⁃stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor⁃κB and nuclear factor of activated T cells pathways[J]. Br J Dermatol, 2020,182(1):147⁃155. doi: 10.1111/bjd.18098.
|
[35] |
Wang S, Li N, Heald P, et al. Flow cytometric DNA ploidy analysis of peripheral blood from patients with sezary syndrome: detection of aneuploid neoplastic T cells in the blood is associated with large cell transformation in tissue[J]. Am J Clin Pathol, 2004,122(5):774⁃782. doi: 10.1309/8B84⁃9FC6⁃PHAP⁃8FDD.
|
[36] |
Prochazkova M, Chevret E, Beylot⁃Barry M, et al. Large cell transformation of mycosis fungoides: tetraploidization within skin tumor large cells[J]. Cancer Genet Cytogenet, 2005,163(1):1⁃6. doi: 10.1016/j.cancergencyto.2005.03.013.
|
[37] |
Laharanne E, Chevret E, Idrissi Y, et al. CDKN2A⁃CDKN2B deletion defines an aggressive subset of cutaneous T⁃cell lymphoma[J]. Mod Pathol, 2010,23(4):547⁃558. doi: 10.1038/modpathol.2009.196.
|
[38] |
Nicolae⁃Cristea AR, Benner MF, Zoutman WH, et al. Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30⁃positive lymphoproliferative disease[J]. Br J Dermatol, 2015,172(3):784⁃788. doi: 10.1111/bjd.13476.
|
[39] |
Sun J, Yi S, Qiu L, et al. SATB1 defines a subtype of cutaneous CD30+ lymphoproliferative disorders associated with a T⁃helper 17 cytokine profile[J]. J Invest Dermatol, 2018,138(8):1795⁃1804. doi: 10.1016/j.jid.2018.02.028.
|
[40] |
Garaicoa FH, Roisman A, Arias M, et al. Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides[J]. Tumour Biol, 2016,37(10):13637⁃13647. doi: 10. 1007/s13277⁃016⁃5259⁃8.
|
[41] |
Qiu L, Liu F, Yi S, et al. Loss of 5⁃hydroxymethylcytosine is an epigenetic biomarker in cutaneous T⁃cell lymphoma[J]. J Invest Dermatol, 2018,138(11):2388⁃2397. doi: 10.1016/j.jid.2018.05. 007.
|
[42] |
Yi S, Sun J, Qiu L, et al. Dual role of EZH2 in cutaneous anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment[J]. J Invest Dermatol, 2018,138(5):1126⁃1136. doi: 10.1016/j.jid.2017.10.036.
|